Silver State Scripts Board Meeting Minutes

Suzanne Bierman, JD, MPH

Date of Meeting: Thursday, September 22, 2022, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agenda Item	genda Item Record			
1. Closed Executive Session				
a. Call to Order and Roll Call	Chairperson Decerbo called the meeting September 22, 2022.	to order at 1:07	p.m. on	DHCFP Staff Present were as follows:
	Chairperson Decerbo took the roll.	Present	Absent	 Lither, Gabriel, Senior Deputy Attorney General (SDAG)
	Mark Decerbo, Pharm.D., Chair	\boxtimes		 Capurro, Antonina, Deputy Administrator
	Kate Ward, Pharm.D., Vice Chair	\boxtimes		Olsen, David, Social
	 Joseph Adashek, MD 	\boxtimes		Services Chief III
	Mark Crumby, Pharm. D.		\boxtimes	 Gudino, Antonio, Social
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes		Services Program
	Mike Hautekeet, R.Ph.		\boxtimes	Specialist III (SSPS)
	Sapandeep Khurana, MD	\boxtimes		Berntson, Kindra, SSPS II
	• Isabella Niezborala, Pharm.D.	\boxtimes		Advantage B. Chaff Barrand
	Aditi Singh, MD	\boxtimes		Magellan Rx Staff Present

		 were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services Soto, Claudia, Sr. Dir. Account Management Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst Hawkins, Tina, VP Account Management Chow, Connie, Pharm.D., Clinical Account Manager Haloski, Kristen, Sr. Dir., Value Based Pricing
b. Financial Review of Drug Classes with Proposed Changes	Chairman Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review. Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting Dr. Mishra presented the Financial Review of the News Drugs, noting the products with proposed changes in PDL status. • Antidotes, Opiate Antagonists, Substance Abuse Agents • Atopic Dermatitis • Alzheimer's Agents • Antiparkinsonian Agents	

	 Monoclonal Antibodies for the Tre Conditions Tramadol and Related Drugs Growth Hormone Modifiers Incretin Mimetics and Combination Dr. Mishra presented the Financial Review Reviewed for Possible Addition, noting the changes in PDL status. Colony Stimulating Factors Dr. Mishra presented the Financial Review Classes with Proposed Changes, noting the changes in PDL status. MS Agents Proton Pump Inhibitors Androgens Anticonvulsants Anti-migraine Atypical Antipsychotics 	ons ons of the New Drug Classes Being e products with proposed of the Established Drug	
2. Open Public Meeting			
a. Call to Order and Roll Call	Chairman Decerbo called the meeting to of September 22, 2022. A quorum was present.	order at 2:07 p.m. on	 DHCFP Staff Present were as follows: Lither, Gabriel, SDAG Capurro, Antonina, Deputy Administrator
	Chairman Decerbo took the roll.	Present Absent	 Olsen, David, Social Services Chief III Gudino, Antonio, SSPS III
	Mark Decerbo, Pharm.D., ChairKate Ward, Pharm.D., Vice Chair		Berntson, Kindra, SSPS II, Pharmacy Unit
			Magellan Rx Staff Present

	 Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Aditi Singh, MD 			 were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services Soto, Claudia, Sr. Dir. Account Management Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst Hawkins, Tina, VP Account Management The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured
b. Approval for previous Meeting Minutes from June 23,2022	By unanimous consent, the minutes were	e approved as	revised.	
c. Public Comments	Telephonic and web comment was called opened. Public comment was provided by Robin F National Alliance on Mental Illness (NAM Public comment was provided by Kelly Fr for the Washoe County Sheriff's Office Io	Reedy Executiv II) Nevada. ederick, RN w	re Director of ith MAP Program	

	Public comment was provided by Sandra Boxx, RN with Northern Nevada Hopes, located in Reno, NV.	
d. Status Update by DHCFP	 Chief of Pharmacy Services, David Olsen, provided five announcements. Today Governor Sisolak has announced the launch of Array RX. This is a digital discount card for prescription drugs. All Nevadans should be able to access the free discount card regardless of age or income using the digital card to help save up to 80% on certain medications. The card went live on Monday. The program is not part of Medicaid pharmacy benefit, as Medicaid has an open formulary and drugs that are FDA approved and medically necessary to rebate eligible or covered for beneficiaries. However, there may be cases where beneficiaries purchase drugs for other use, and they would be able to use this discount card. As part of the recent change of Pharmacy Benefit Manager (PBM) vendor, Pharmacy information and related updates are housed at a new website: https://nevadamedicaid.magellanrx.com Nevada Medicaid is joining the National Medicaid Pooling Initiative (NMPI). Additionally, we are also able to note that we are joining the Diabetic Supply Pool. This change will occur on October 1st of this year. For more information regarding NMPI, you can contact two individuals at Magellan Medicaid Administration. They are Eileen Zimmer and her e-mail address is eezimner@magellanhealth.com and Kristen Haloski and her e-mail is kmhaloski@magellanhealth.com. Nevada Medicaid has established licensed pharmacists as a new provider type. Services related to dispensing self-administered contraceptives and prescribing HIV prevention medications are now reimbursable when provided by a pharmacist enrolled as a Nevada Medicaid provider. For more information on how to enroll as a 	

	Nevada Medicaid provider, please visit the Provider Enrollment page	
	that is found at the website www.medicaid.nv.gov .	
	Nevada Medicaid also hosted a public workshop concerning a	
	project to manage physician administer drugs (PAD). A list of 60	
	specialty physician administrated drugs requiring prior	
	authorization was presented at this workshop. These prior	
	authorizations will not be required until this project is	
	implemented, is tentatively scheduled for the first half of next	
	year.	
e. Bylaws	 Announcement to the Board Members, as well as the public, some of the guiding parameters going forward. Theres nothing too substantial that codifies numbers a little bit. 1/3 pharmacist 1/3 physicians' locks in the total number between 5:00 and 11:00. Correction of time for public comment which was always 3 minutes previously, but 5 minutes somehow got snuck in there, but that has been fixed. Information on NMAP regarding inclusion of a duty. SSSB to serve in an advisory capacity for the Nevada Medicaid Assistance Program. This is also known as the AIDS Drug Assistance Program. The requirement would be for this board to advise on the program 	
	formulary at least on an annual basis.	
3. Clinical Presentations		
A. For Possible Action: Discussion and possible adoption of TOXICOLOGY AGENTS – Antidotes - Opiate Antagonists		
i. <u>Public comment</u>	Telephonic and web comment was called for, and the phone lines were opened.	
	Public comment was provided by Kenneth Berry. Pharmacist and	
	Medical Science Director with Alchemies.	

ii.	Drug class review presentation by MagellanRx	Dr. Mishra discussed Zimhi, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.					
		Dr. Mishra recommended the Board con therapeutically equivalent.	sider the cl	ass clin	ically and		
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Magellan, and Vice-Chair Ward seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
			Yes	No	Abst.		
		 Mark Decerbo, Pharm.D., Chair 					
		Kate Ward, Pharm.D., Vice Chair	\boxtimes				
		 Joseph Adashek, MD 	\boxtimes				
		Mark Crumby, Pharm.D			\boxtimes		
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
		Mike Hautekeet, R.Ph.			\boxtimes		
		 Sapandeep Khurana, MD 	\boxtimes				
		Isabella Niezborala, Pharm.D	\boxtimes				
		Aditi Singh, MD	\boxtimes				
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Zimhi on the PDL as non-preferred.					
٧.	Discussion by Board and	Chairman Decerbo moved to approve the	e proposed	change	es as		
	action by Board for approval of drugs for inclusion on the PDL.		presented by Magellan and Board Member Gonzalez seconded the				

	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	Joseph Adashek, MD	\boxtimes			
	Mark Crumby, Pharm.D			\boxtimes	
	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Mike Hautekeet, R.Ph.			\boxtimes	
	Sapandeep Khurana, MD	\boxtimes			
	 Isabella Niezborala, Pharm.D 	\boxtimes			
	Aditi Singh, MD	\boxtimes			
B. For Possible Action: Discussion and possible adoption of TOXICOLOGY AGENTS – Antidotes – Substance Abuse Agents					
i. <u>Public comment</u>	Telephonic and web comment was called opened. No public comment was provided.	l for, and th	ie phoi	ne lines were	
ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Lucemyra, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies. Dr. Mishra recommended the Board consider the class clinically and				
	therapeutically equivalent.			,	
iii. Discussion by Board	Chairman Decerbo moved to accept the	lass as clini	cally a	nd	
and action by Board to	therapeutically equivalent presented by				

	approve clinical/therapeutic	Adashek seconded the motion.				
	equivalency of agents	A vote was taken, and the results were as follows from members in				
	in class.	attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 	\boxtimes			
		 Mark Crumby, Pharm.D. 			\boxtimes	
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes			
		 Mike Hautekeet, R.Ph. 			\boxtimes	
		 Sapandeep Khurana, MD 	\boxtimes			
		 Isabella Niezborala, Pharm.D. 	\boxtimes			
		Aditi Singh, MD	\boxtimes			
iv.	Presentation of	Dr. Mishra recommended adding Luce	•		•	
	recommendations for	naltrexone oral as preferred and remo	oving Bunavail	as me	dication has	
	PDL inclusion by	been disconnected by manufacture.				
	MagellanRx					
V.	Discussion by Board and	Chairman Decerbo moved to approve	the proposed	chang	ac ac	
٧.	action by Board for	presented by Magellan and Board Me		_		
	approval of drugs for	motion.	Zilibel Addsilei	(30001	ided the	
	inclusion on the PDL.	medem.				
		A vote was taken, and the results were	e as follows fro	om me	mbers in	
		attendance (in favor, against, and abs	stentions wher	e appli	cable):	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 	\boxtimes			
		Mark Crumby, Pharm.D			\boxtimes	

		T	1
	• Elizabeth Gonzalez, Pharm.D.		
	• Mike Hautekeet, R.Ph.		
	• Sapandeep Khurana, MD		
	■ Isabella Niezborala, Pharm.D □		
	■ Aditi Singh, MD		
vi. Board Member	Dr. Khurana recommend sending to the DUR Board to	have PA criteria	
Comment	removed for Vivitrol.		
C. For Possible Action: Discussion			
and possible adoption of			
Atopic Dermatitis			
i. Public Comment	Tolonbonic and wob comment was called for and the	nhana linas wara	
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the opened.	phone lines were	
	opened.		
	Public comment was provided by Brandon Yip, a Field	Medical	
	Pharmacist for Sanofi.	ivicuicai	
	That madist for Sanom		
ii. Drug class review	Dr. Mishra discussed Adbry Inj, Cibingo Tab and Opze	lura Topical, the	
presentation by	new product within this drug class. He presented the	•	
MagellanRx	the drug class and noted the indication, mechanism of	f action, and	
	efficacy studies.		
	Dr. Mishra recommended the Board consider the class	s clinically and	
	therapeutically equivalent.		
Bis site 1 Br	Chairman Brooks are all the chairman and the chairman are all the chairman and the chairman are all the chairman a		
iii. Discussion by Board	Chairman Decerbo moved to accept the class as clinic	•	
and action by Board to	therapeutically equivalent presented by Magellan and Adashek seconded the motion.	i Board Member	
approve clinical/therapeutic	Audstiek Seconded the motion.		
equivalency of agents in	A vote was taken, and the results were as follows from	n memhers in	
class.	attendance (in favor, against, and abstentions where		
Ciuss.	attendance (in lavor, against, and abstentions where	applicable).	

		Yes	No	Abst.	
	 Mark Decerbo, Pharm.D., Chair 	\boxtimes			
	 Kate Ward, Pharm.D., Vice Chair 	\boxtimes			
	 Joseph Adashek, MD 	\boxtimes			
	Mark Crumby, Pharm.D			\boxtimes	
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes			
	Mike Hautekeet, R.Ph.			\boxtimes	
	Sapandeep Khurana, MD	\boxtimes			
	 Isabella Niezborala, Pharm.D 	\boxtimes			
	Aditi Singh, MD	\boxtimes			
iv. Presentation of	Dr. Mishra recommended adding Adbry	Inj, Cibinqo	Tab, O	pzelura	
recommendations for PDL inclusion by	Topical on the PDL as non-preferred.				
MagellanRx					
Widgellatilix					
v. Discussion by Board and	Board Member Adashek moved to appro	ve the prop	osed c	hanges as	
action by Board for	presented by Magellan and Board Memb	er Gonzale	z secoi	nded the	
approval of drugs for	motion.				
inclusion on the PDL.	A	- f - II f			
	A vote was taken, and the results were as				
	attendance (in favor, against, and abster	itions wher	е арріі	cable):	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	Joseph Adashek, MD	\boxtimes			
	Mark Crumby, Pharm.D			\boxtimes	
	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Mike Hautekeet, R.Ph.			\boxtimes	
	Sapandeep Khurana, MD	\boxtimes			
	Isabella Niezborala, Pharm.D	\boxtimes			
	Aditi Singh, MD	\boxtimes			

D. For Possible Action: Discussion and possible adoption of Alzheimer's Agents					
i. <u>Public Comment</u>	Telephonic and web comment was calle opened.				
	Public comment was provided by Mitra Liaison with Corium.	Patel, Senio	r Medio	cal Science	
ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Adlarity, the new p presented the availability within the dru mechanism of action, and efficacy studies				
	Dr. Mishra recommended the Board con therapeutically equivalent.	isider the cla	ass clin	ically and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Board Member Gonzalez moved to accept therapeutically equivalent presented by Adashek seconded the motion.				
equivalency of agents in class.	A vote was taken, and the results were a attendance (in favor, against, and abster				
	I	Yes	No	Abst.	
	 Mark Decerbo, Pharm.D., Chair 	\boxtimes			
	 Kate Ward, Pharm.D., Vice Chair 	\boxtimes			
	 Joseph Adashek, MD 	\boxtimes			
	 Mark Crumby, Pharm.D 			\boxtimes	
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes			
	 Mike Hautekeet, R.Ph. 			\boxtimes	

		Sapandeep Khurana, MD	\boxtimes					
		 Isabella Niezborala, Pharm.D 	\boxtimes					
		Aditi Singh, MD	\boxtimes					
iv.	Presentation of	Dr. Mishra recommended adding Adlar	ity Patch on i	the PDI	L as non-			
	recommendations for PDL	preferred.						
	inclusion by MagellanRx							
٧.	Discussion by Board and	Chairman Decerbo moved to approve the	ne proposed	change	es as		 	
	action by Board for	presented by Magellan and Board Mem		_				
	approval of drugs for inclusion on the PDL.	motion.						
		A vote was taken, and the results were	as follows fro	om mei	mbers in			
		attendance (in favor, against, and abste						
			Yes	No	Abst.			
		Mark Decerbo, Pharm.D., Chair	\boxtimes					
		Kate Ward, Pharm.D., Vice Chair	\boxtimes					
		 Joseph Adashek, MD 	\boxtimes					
		Mark Crumby, Pharm.D			\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes					
		Mike Hautekeet, R.Ph.			\boxtimes			
		Sapandeep Khurana, MD	\boxtimes					
		Isabella Niezborala, Pharm.D	\boxtimes					
		Aditi Singh, MD	\boxtimes					
vi.	Board Member comments	Board Member Khurana recommended	to review th	ne med	ication		 	
		utilization in six months.					 	
_	r Possible Action: Discussion							
	d possible adoption of							
An	tiparkinsonian Agents							
						1		

i.	<u>Public Comment</u>	Telephonic and web comment was called opened.	for, and the phone lines were
		No public comment was provided.	
ii.	Drug class review presentation by MagellanRx	Dr. Mishra discussed Kynmobi, the new page of the presented the availability within the condition, mechanism of action, and effi	rug class and noted the
		Dr. Mishra recommended the Board constitution therapeutically equivalent.	ider the class clinically and
iii.	Discussion by Board and action by Board to approve clinical/therapeutic	Board Member Khurana moved to accept therapeutically equivalent presented by seconded the motion.	·
	equivalency of agents in class.	A vote was taken, and the results were as attendance (in favor, against, and absten	
			Yes No Abst.
		Mark Decerbo, Pharm.D., Chair	
		Kate Ward, Pharm.D., Vice Chair	
		Joseph Adashek, MD	
		Mark Crumby, Pharm.D.	
		Elizabeth Gonzalez, Pharm.D.	
		Mike Hautekeet, RPh	
		Sapandeep Khurana, MD	
		 Isabella Niezborala, Pharm.D. 	
		Aditi Singh, MD	
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Kynmo	oi on the PDL as non-preferred.

					1
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to approve the presented by Magellan and Board Member G motion. A vote was taken, and the results were as followed attendance (in favor, against, and abstention).				
	Mark Decerbo, Pharm.D., Chair	Yes ⊠	No	Abst. □	
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	Joseph Adashek, MD	\boxtimes			
	Mark Crumby, Pharm.D			\boxtimes	
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Mike Hautekeet, R.Ph.			\boxtimes	
	Sapandeep Khurana, MD	\boxtimes			
	Isabella Niezborala, Pharm.D	\boxtimes			
	Aditi Singh, MD	\boxtimes			
F. For Possible Action: Discussion and possible adoption of Monoclonal Antibodies for the Treatment of Respiratory Conditions				_	
i. <u>Public Comment</u>	Telephonic and web comment was called for, a opened.				
	Public comment was provided by Ben Rosie, Pl Medical Affairs.				
	Public comment was provided by Brandon Yip, for Sanofi.	Field N	∕ledica	l Pharmacist	

ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Tezspire, the new presented the availability within the drumechanism of action, and efficacy studi. Dr. Mishra recommended the Board coutherapeutically equivalent.		
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the therapeutically equivalent presented by seconded the motion. A vote was taken, and the results were a attendance (in favor, against, and absternance)		
	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D Aditi Singh, MD 	Yes No Abst. □	
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Tezsp	ire on the PDL as non-preferred.	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to appropresented by Magellan and Board Memmotion. A vote was taken, and the results were a		

	attendance (in favor, against, and abstentions where applicable):	
	attenuance (in lavor, against, and abstentions where applicable).	
	Yes No Abst. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D Aditi Singh, MD	
G. For Possible Action: Discussion and possible adoption of Mixed Acting Opioid Analgesics		
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Seglentis, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies. Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Ward seconded the motion.	

	equivalency of agents in	A vote was taken, and the results were a				
	class.	attendance (in favor, against, and abster				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair				
		Kate Ward, Pharm.D., Vice Chair				
		Joseph Adashek, MD	\boxtimes			
		Mark Crumby, Pharm.D			\boxtimes	
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Mike Hautekeet, R.Ph.			\boxtimes	
		Sapandeep Khurana, MD	\boxtimes			
		Isabella Niezborala, Pharm.D	\boxtimes			
		Aditi Singh, MD	\boxtimes			
•	D	Du Mishan managan dad adding Carley	4: 4b - D	DI		
iv.	Presentation of recommendations for PDL	Dr. Mishra recommended adding Seglen	tis on the P	DL as r	ion-preferrea.	
	inclusion by MagellanRx					
V	Discussion by Board and	Chairman Decerbo moved to approve the	nronosed	chang		
٧.	action by Board for	presented by Magellan and Board Meml		_		
	approval of drugs for	motion.				
	inclusion on the PDL.					
		A vote was taken, and the results were a	s follows fro	om me	mbers in	
		attendance (in favor, against, and abster	ntions wher	e appli	cable):	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair				
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		Joseph Adashek, MD	\boxtimes			
		Mark Crumby, Pharm.D				
		Elizabeth Gonzalez, Pharm.D.				
		Mike Hautekeet, R.Ph.				
		Sapandeep Khurana, MD				
		Isabella Niezborala, Pharm.D				
		- isabelia Niezbolala, Filalili.D		ш		

	Aditi Singh, MD	\boxtimes			
H. For Possible Action: Discussion and possible adoption of Growth Hormone Modifiers					
i. <u>Public Comment</u>	Telephonic and web comment was called for opened. No public comment was provided.	r, and th	ne phor	ne lines were	
ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Skytrofa, the new proc presented the availability within the drug cl mechanism of action, and efficacy studies. Dr. Mishra recommended the Board consident therapeutically equivalent.	ass and I	noted t	the indication	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the class therapeutically equivalent presented by Ma Adashek seconded the motion. A vote was taken, and the results were as for attendance (in favor, against, and abstention)				
	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD 	Yes	No	Abst.	

	Isabella Niezborala, Pharm.DAditi Singh, MD		
	, value on gri, me		
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Skytr and moving Nutropin AQ from non-pre		
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to appropriate presented by Magellan and Board Memmotion.		
	A vote was taken, and the results were attendance (in favor, against, and abste		
		Yes No Abst.	
	Mark Decerbo, Pharm.D., Chair		
	Kate Ward, Pharm.D., Vice Chair		
	Joseph Adashek, MD		
	Mark Crumby, Pharm.D		
	Elizabeth Gonzalez, Pharm.D.		
	Mike Hautekeet, R.Ph.		
	Sapandeep Khurana, MD		
	 Isabella Niezborala, Pharm.D 		
	Aditi Singh, MD		
 For Possible Action: Discussion and possible adoption of Incretin Mimetics and Combinations 			
i. Public Comment	Telephonic and web comment was call	ed for, and the phone lines were	

		opened.			
		Public comment was provided by Mich	ael Shenherd	l with F	ili Lilly
ii.	Drug class review	Dr. Mishra discussed Mounjaro, the ne	•		•
	presentation by	He presented the availability within the	•		_
	MagellanRx	indication, mechanism of action, and e	fficacy studie	es.	
		Dr. Mishra recommended the Board co	nsider the cl	ass clin	ically and
		therapeutically equivalent.			
iii.	Discussion by Board and	Board Member Adashek moved to acce	pt the class	as clinic	cally and
	action by Board to	therapeutically equivalent presented b	y Magellan a	nd Cha	irman
	approve	Decerbo seconded the motion.			
	clinical/therapeutic	A vista visa takan and the manulta visus	aa fallaa fu		h - u - i -
	equivalency of agents in class.	A vote was taken, and the results were attendance (in favor, against, and abste			
	Class.	attendance (iii lavoi, against, and abste	entions when	с аррп	cablej.
			Yes	No	Abst.
		Mark Decerbo, Pharm.D., Chair	\boxtimes		
		Kate Ward, Pharm.D., Vice Chair	\boxtimes		
		 Joseph Adashek, MD 	\boxtimes		
		Mark Crumby, Pharm.D			\boxtimes
		Elizabeth Gonzalez, Pharm.D.	\boxtimes		
		Mike Hautekeet, R.Ph.			\boxtimes
		Sapandeep Khurana, MD	\boxtimes		
		Isabella Niezborala, Pharm.D			
		Aditi Singh, MD			
iv.	Presentation of	Dr. Mishra recommended adding Mour	njaro on the	PDL as	non-
	recommendations for PDL inclusion by MagellanRx	preferred.			
	inclusion by Magenantx				
V.	Discussion by Board and	Board Member Adashek moved to prop	osed change	s as pre	sented by
	action by Board for	Magellan and Board Member Gonzalez	seconded th	e moti	on.

approval of drugs for						
inclusion on the PDL.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
	Yes No Abst.					
	 Mark Decerbo, Pharm.D., Chair 	\boxtimes				
	 Kate Ward, Pharm.D., Vice Chair 	\boxtimes				
	 Joseph Adashek, MD 	\boxtimes				
	 Mark Crumby, Pharm.D 			\boxtimes		
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
	 Mike Hautekeet, R.Ph. 			\boxtimes		
	 Sapandeep Khurana, MD 	\boxtimes				
	 Isabella Niezborala, Pharm.D 	\boxtimes				
	Aditi Singh, MD					
vi. Board Member Comment		Board member Khurana recommending for DUR Board to review the				
	Prior authorization criteria for this drug.					
J. For Possible Action: Discussion and possible adoption of						
Colony Stimulating Factors						
i. <u>Public Comment</u>	Telephonic and web comment was called opened.	Telephonic and web comment was called for, and the phone lines were opened.				
	No public comment was provided.					
ii. New Drug class review presentation by MagellanRx	Dr. Mishra discussed adding a new drug class to the PDL. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.					
	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.					

iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in					
class.	attendance (in favor, against, and abste	attendance (in favor, against, and abstentions where applicable):				
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	Joseph Adashek, MD	\boxtimes				
	Mark Crumby, Pharm.D			\boxtimes		
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Mike Hautekeet, R.Ph.			\boxtimes		
	Sapandeep Khurana, MD	\boxtimes				
	Isabella Niezborala, Pharm.D	\boxtimes				
	Aditi Singh, MD	\boxtimes				
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding all the drug class Colony Stimulating Factors to		nted i	n the new		
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to appromage Magellan and Board Member Gonzalez exception of moving Neupogen vial to p dosage forms.	seconded the	e moti	on with the		
	A vote was taken, and the results were a attendance (in favor, against, and abste					
	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD 	Yes ⊠ □ ⊠	No □ ⊠	Abst.		

	 Mark Crumby, Pharm.D Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D Aditi Singh, MD 	
K. For Possible Action: Discussion and possible adoption of MS Agents		
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Kanda Bio HR Associate Director with Bristol-Myers Squibb. Public comment was provided by Amy Hall on behalf of Janssen Scientific Affairs. Public comment was provided by Kaysen Bala Pharmacist and Medical Account Director with Biogen.	
ii. Drug class review presentation by MagellanRx	Dr. Mishra presented the changes within this drug class. Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	

		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	 Joseph Adashek, MD 	\boxtimes				
	 Mark Crumby, Pharm.D 			\boxtimes		
	 Elizabeth Gonzalez, Pharm.D. 	\boxtimes				
	Mike Hautekeet, R.Ph.			\boxtimes		
	Sapandeep Khurana, MD	\boxtimes				
	 Isabella Niezborala, Pharm.D 	\boxtimes				
	Aditi Singh, MD	\boxtimes				
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommending moving gener preferred to preferred and moving branch non-preferred.					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	presented by Magellan and Board Membership. A vote was taken, and the results were as	Chairman Decerbo moved to approve the proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	 Joseph Adashek, MD 	\boxtimes				
	Mark Crumby, Pharm.D			\boxtimes		
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Mike Hautekeet, R.Ph.			\boxtimes		
	Sapandeep Khurana, MD	\boxtimes				
	Isabella Niezborala, Pharm.D	\boxtimes				
	Aditi Singh, MD	\boxtimes				

L. For Possible Action: Discussion					
and possible adoption of					
Proton Pump Inhibitors					
i. <u>Public Comment</u>	Telephonic and web comment was called	ed for, and th	e phor	ne lines were	
	opened.				
	No public comment was provided.				
ii. Drug class review	Dr. Mishra, presented the changes with	in this drug o	lass.		
presentation by					
MagellanRx	Dr. Mishra recommended the Board co	nsider the cla	ass clin	ically and	
	therapeutically equivalent.				
iii. Discussion by Board and	Chairman Decerbo moved to accept the	class as clini	cally a	nd	
action by Board to	therapeutically equivalent presented by	/ Magellan ar	nd Boa	rd Member	
approve	Adashek seconded the motion.				
clinical/therapeutic					
equivalency of agents in	A vote was taken, and the results were a	as follows fro	m mer	nbers in	
class.	attendance (in favor, against, and abste	ntions where	e appli	cable):	
		Yes	No	Abst.	
	 Mark Decerbo, Pharm.D., Chair 	\boxtimes			
	 Kate Ward, Pharm.D., Vice Chair 	\boxtimes			
	 Joseph Adashek, MD 	\boxtimes			
	 Mark Crumby, Pharm.D 			\boxtimes	
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	 Mike Hautekeet, R.Ph. 			\boxtimes	
	 Sapandeep Khurana, MD 	\boxtimes			
	 Isabella Niezborala, Pharm.D 	\boxtimes			
	Aditi Singh, MD	\boxtimes			
iv. Presentation of	Dr. Mishra recommended adding suspe	nsion to the	PDL. R	ecommending	
recommendations for	adding brand Protonix Susp as preferred			_	
	as non-preferred.	5			

PDL inclusion by MagellanRx				
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Gonzalez moved to approve th presented by Magellan and Board Member Admotion.			
	A vote was taken, and the results were as follo attendance (in favor, against, and abstentions			
M. For Possible Action: Discussion and possible adoption of	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D Aditi Singh, MD 	Yes No		
Androgens i. <u>Public Comment</u>	Telephonic and web comment was called for, a opened.			
ii. Drug class review presentation by MagellanRx	No public comment was provided. Dr. Mishra presented the changes within this of the changes within the changes within the changes within this of the changes within this of the changes within the changes within this of the changes within the changes wi		inically and	

action clinica	ssion by Board and by Board to approve al/therapeutic alency of agents in	Chariman Decerbo moved to accept therapeutically equivalent presented Gonzalez seconded the motion. A vote was taken, and the results wer attendance (in favor, against, and abs				
			Yes	No	Abst.	
		 Mark Decerbo, Pharm.D., Chair 				
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		Joseph Adashek, MD	\boxtimes			
		Mark Crumby, Pharm.D			\boxtimes	
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes			
		 Mike Hautekeet, R.Ph. 			\boxtimes	
		Sapandeep Khurana, MD	\boxtimes			
		Isabella Niezborala, Pharm.D	\boxtimes			
		Aditi Singh, MD	\boxtimes			
	ntation of nmendations for PDL ion by MagellanRx	Dr. Mishra recommended moving An	idrogen gel pun	np to p	referred.	
action appro	ssion by Board and by Board for val of drugs for ion on the PDL.	Chairman Decerbo moved to approve presented by Magellan and Board Memotion.	•	_		
		A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 	\boxtimes			
		Mark Crumby, Pharm.D			\boxtimes	

	FIT of the Control of				-
	Elizabeth Gonzalez, Pharm.D.				
	 Mike Hautekeet, R.Ph. 			\boxtimes	
	 Sapandeep Khurana, MD 	\boxtimes			
	 Isabella Niezborala, Pharm.D 	\boxtimes			
	 Aditi Singh, MD 	\boxtimes			
N. For Possible Action: Discussion					
and possible adoption of					
Anticonvulsants					
i. Public Comment	Telephonic and web comment was cal	led for and th	e nhon	e lines were	
i. <u>rabiic comment</u>	opened.	ieu ioi, aliu tii	ie piloti	e iiiles were	
	opened.				
	Public comment was provided by Debl	oie Chef a Met	taphor	and Aids on	
	Interrelates.				
	Public comment was provided by Sand	lhar Raj Pharm	n D with	n Medical	
	Affairs.	•			
	Public comment was provided by Deb	Profant with J	azz Pha	rmaceuticals.	
	Public comment was provided by Brian	n Wentzel with	า Healtl	n Economics	
	and Outcomes Research Liaison with S	ynovial, which	n is base	ed out of	
	Marlboro, Massachusetts.				
	Public comment was provided by Alex	ander Scurry v	vith MS	SL with ECB.	
			•		
ii. Drug class review	Dr. Mishra presented the changes with	nin this drug cl	lass.		
presentation by	Do Mishus assessmented the December	a mastal a malla e i di			
MagellanRx	Dr. Mishra recommended the Board of	onsider the cla	iss ciini	cally and	
	therapeutically equivalent.				
iii. Discussion by Board and	Board Member Adashek moved to acc	ent the class a	s clinic	ally and	
action by Board to	therapeutically equivalent presented by				
action by board to	and appearitually equivalent presented t	77 ITIUDCIIUII UI	.a chai		

approve	Decerbo seconded the motion.						
clinical/therapeutic							
equivalency of agents in		A vote was taken, and the results were as follows from members in					
class.	attendance (in favor, against, and abster	attendance (in favor, against, and abstentions where applicable):					
		Yes	No	Abst.			
	Mark Decerbo, Pharm.D., Chair						
	Kate Ward, Pharm.D., Vice Chair	\boxtimes					
	Joseph Adashek, MD	\boxtimes					
	Mark Crumby, Pharm.D			\boxtimes			
	Elizabeth Gonzalez, Pharm.D.	\boxtimes					
	Mike Hautekeet, R.Ph.			\boxtimes			
	Sapandeep Khurana, MD	\boxtimes					
	Isabella Niezborala, Pharm.D	\boxtimes					
	Aditi Singh, MD	\boxtimes					
iv. Presentation of	Dr. Raj Mishra recommended adding sol	utions to th	e drug	class.			
recommendations for	Recommending adding generic lascosam	ide solutior	n and le	evetiracetam			
PDL inclusion by	solution as preferred. Also adding brand	Keppra Sol	ution a	nd Vimpat			
MagellanRx	solution as non-preferred.						
v. Discussion by Board and	Board Member Gonzalez moved to appro	ove the pro	posed (changes as			
action by Board for	presented by Magellan and Board Memb			-			
approval of drugs for	motion.						
inclusion on the PDL.							
	A vote was taken, and the results were a						
	attendance (in favor, against, and abster	ntions wher	e appli	cable):			
		Yes	No	Abst.			
	Mark Decerbo, Pharm.D., Chair	\boxtimes					
	Kate Ward, Pharm.D., Vice Chair	\boxtimes					
	Joseph Adashek, MD	\boxtimes					
	Mark Crumby, Pharm.D			\boxtimes			
	Elizabeth Gonzalez, Pharm.D.	\boxtimes					
		_					

	Mike Hautekeet, R.Ph.	
	Sapandeep Khurana, MD	
	■ Isabella Niezborala, Pharm.D □ □ □	
	■ Aditi Singh, MD	
O. For Possible Action: Discussion and possible adoption of Antimigraine - Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists		
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.	
	Public comment was provided by Rochelle Yang with the Field Medical Affairs Team at HAVA.	
ii. Drug class review presentation by MagellanRx	Dr. Mishra presented the changes within this drug class. Dr. Mishra recommended the Board consider the class clinically and	
	therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Chairman Decebro moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.	
equivalency of agents in class.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
	Yes No Abst.	
	■ Mark Decerbo, Pharm.D., Chair □ □ □	
	■ Kate Ward, Pharm.D., Vice Chair □ □ □	
	■ Joseph Adashek, MD	
	Mark Crumby, Pharm.D	

	Elizabeth Gonzalez, Pharm.D.		
	Mike Hautekeet, R.Ph.		
	Sapandeep Khurana, MD		
	Isabella Niezborala, Pharm.D		
	Aditi Singh, MD		
iv. Presentation of	Dr. Mishra recommending changing Uk	orelvy from non-preferred to	
recommendations for	preferred.		
PDL inclusion by			
MagellanRx			
v. Discussion by Board and	Board Member Gonzalez moved to app	prove the proposed changes as	
action by Board for	presented by Magellan and Board Mer		
approval of drugs for	motion.		
inclusion on the PDL.			
	A vote was taken, and the results were		
	attendance (in favor, against, and abst	entions where applicable):	
		Yes No Abst.	
	Mark Decerbo, Pharm.D., Chair		
	Kate Ward, Pharm.D., Vice Chair		
	Joseph Adashek, MD		
	Mark Crumby, Pharm.D		
	Elizabeth Gonzalez, Pharm.D.		
	Mike Hautekeet, R.Ph.		
	Sapandeep Khurana, MD		
	Isabella Niezborala, Pharm.D		
	Aditi Singh, MD		
	- 5 /		
P. For Possible Action: Discussion			
and possible adoption of Anti-			

	graine – Serotonin-Receptor onists (Triptans)					
i.	Public Comment	Telephonic and web comment was called opened.				
		No public comment was provided.				
ii.	Drug class review presentation by	Dr. Mishra presented the changes within	this drug c	lass.		
	MagellanRx	Dr. Mishra recommended the Board con therapeutically equivalent.	sider the cla	ass clin	ically and	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept therapeutically equivalent presented by Gonzalez seconded the motion. A vote was taken, and the results were a attendance (in favor, against, and abster				
			Yes	No	Abst.	
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes			
		 Kate Ward, Pharm.D., Vice Chair 	\boxtimes			
		 Joseph Adashek, MD 	\boxtimes			
		 Mark Crumby, Pharm.D 			\boxtimes	
		 Elizabeth Gonzalez, Pharm.D. 	\boxtimes			
		 Mike Hautekeet, R.Ph. 			\boxtimes	
		 Sapandeep Khurana, MD 	\boxtimes			
		 Isabella Niezborala, Pharm.D 	\boxtimes			
		Aditi Singh, MD	\boxtimes			

iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommending moving Imitre preferred and moving zolmitriptan nasal preferred.				
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to approve th presented by Magellan and Board Meml motion.				
	A vote was taken, and the results were a				
	attendance (in favor, against, and abster	itions where	e appıı	cable):	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	 Joseph Adashek, MD 	\boxtimes			
	Mark Crumby, Pharm.D			\boxtimes	
	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Mike Hautekeet, R.Ph.			\boxtimes	
	Sapandeep Khurana, MD	\boxtimes			
	Isabella Niezborala, Pharm.D	\boxtimes			
	Aditi Singh, MD	\boxtimes			
Q. For Possible Action: Discussion and possible adoption of Atypical Antipsychotics					
i. <u>Public Comment</u>	Telephonic and web comment was called opened.	d for, and th	e phoi	ne lines were	
	Public comment was provided by Even It Development and Commercialization.	alian with P	harma	ceutical	
	Public comment was provided by Kenne	th Perry wit	h Alche	emies.	

ii.	Drug class review presentation by	Dr. Mishra presented the changes within	this drug c	lass.		
	MagellanRx	Dr. Mishra recommended the Board con	sider the cla	ass clin	ically and	
	-	therapeutically equivalent.			·	
iii.	Discussion by Board and	Chairman Decebro moved to accept the	class as clin	ically a	nd	
	action by Board to approve	therapeutically equivalent presented by	Magellan a	nd Boa	rd Member	
	clinical/therapeutic equivalency of agents in	Gonzalez seconded the motion.				
	class.	A vote was taken, and the results were a	s follows fro	om mei	mbers in	
		attendance (in favor, against, and abster				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 	\boxtimes			
		Mark Crumby, Pharm.D			\boxtimes	
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Mike Hautekeet, R.Ph.			\boxtimes	
		Sapandeep Khurana, MD	\boxtimes			
		 Isabella Niezborala, Pharm.D 	\boxtimes			
		Aditi Singh, MD	\boxtimes			
iv.	Presentation of	Dr. Mishra recommended moving brand	name Geod	don fro	m preferred	
	recommendations for PDL	to non-preferred and ziprasidone from r	on-preferre	ed to p	referred.	
	inclusion by MagellanRx					
٧.	Discussion by Board and	Board Member Adashek moved to appro			-	
	action by Board for	presented by Magellan and Board Meml	oer Gonzale	z secor	nded the	
	approval of drugs for inclusion on the PDL.	motion.				
		A vote was taken, and the results were a	s follows fro	m mei	mbers in	
		attendance (in favor, against, and abster				

	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D Elizabeth Gonzalez, Pharm.D. Mike Hautekeet, R.Ph. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D Aditi Singh, MD 	Yes	No	Abst. □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	
R. Annual Review – Drug Classes without proposed changes					
i. Public comment	Telephonic and web comment was called opened. Public comment was provided by Patrick Comment was provided by Board Memb infectives PA criteria.				
ii. Discussion by Board and action by Board for approval of the annual review drug classes without proposed changes.	Chairman Decerbo moved to approve the without proposed changes as presented Member Adashek seconded the motion. A vote was taken, and the results were as attendance (in favor, against, and absten Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair				

	Joseph Adashek, MD	\boxtimes			
	Mark Crumby, Pharm.D			\boxtimes	
	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Mike Hautekeet, R.Ph.			\boxtimes	
	Sapandeep Khurana, MD	\boxtimes			
	Isabella Niezborala, Pharm.D	\boxtimes			
	Aditi Singh, MD	\boxtimes			
S. MagellanRx Reports	MRx Pipeline- Upcoming specialty and traditional Drugs				
	Recent FDA Approvals				
	Upcoming Biosimilars- Colony Stimulating Factors				
T. Closing Discussion					
i. Public comments on any	No public comments were provided.				
subject					
ii. Date and location of the	Date: December 15, 2022.				
next meeting.	Location: TBD				
iii. Adjournment	Chairman Decerbo adjourned the meet	ng at 4:50 P	M.		

Attachment A – Members of the Public in Attendance

Craig Irwin	Deb Profant	GARCIA Fabiola	Joe Germain
David Large	David Block	John Breen	Hamson, Rodney
Geoffrey Robinson	Lovan, Charlie R	Kenneth Berry	Jonathan
Jason C Bott	Darin Cecil	Tom Telly	Sullivan, Mike
Wettestad, Phil	Susan De Marco	Scurry Alexandra	Sandhar Raj
Rochelle Yang	Rianna White	Phillip Santa Maria	Patrick Harvey
Maitrey Patel	Michael E Shepherd	Martin Mercy	Ben Skoog
Angela Bedenbaugh	Donna Laffey	Sandra Boxx	Yip, Brandon
David West	Robinson, Lovell R	Duong, Celine	Bayo, KayOnda
Waring, Ashlee	Hertzberg, Susan	Melisa McEwen	Lim, Luke
SANTARONE, CHRISTOPHER	Robin Reedy	Michele	Tyler Shaw
DeFelice Elaine	Wensel, Brian	Ameen Rejena	

Attachment B – Submitted Written Comment

BOVRICK INTEGRATED HEALTH Carson Tahoe Hospital's Behavioral Health Services Emgality

<u>Lybalvi</u> <u>MAT Medications</u> <u>National Alliance on Mental Illness</u>

<u>CHILD NEUROLOGY</u> <u>Solidarity Mental Health Services LLC</u> <u>Upcoming Review of Medicaid Formulary</u>

Spine and PainErica FredenburghLas Vegas Skin and Cancer ClinicNeurologyNNAMHSNorthern Nevada HOPES Clinic

Antipsychotic testimony UNLV School of Medicine Well Care Pharmacy

Las Vegas Psych Services Comments Hundley Foundation Alliance Mental Health Specialists PLLC

Epilepsy Foundtion Valtoco and Fintepla